Gold-facilitated in situ hybridization: A bright-field autometallographic alternative to fluorescence in situ hybridization for detection of HER-2/neu gene amplification

American Journal of Pathology

Volumn 160, Issue 5, 2002, Pages 1589-1595

  Tubbs, Raymond ^a   Pettay, James ^a   Skacel, Marek ^a   Powell, Richard ^b   Stoler, Mark ^c   Roche, Patrick ^d   Hainfeld, James ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Nanoprobes Incorporated   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOLD; MESSENGER RNA; NANOPARTICLE; ONCOPROTEIN; STREPTAVIDIN;

ARTICLE; AUTOMETALLOGRAPHY; BREAST CARCINOMA; BRIGHT FIELD MICROSCOPY; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; ONCOGENE NEU; PRIORITY JOURNAL; SIGNAL DETECTION; VALIDATION PROCESS;

EID: 0036094229     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61106-6     Document Type: Article

References (43)

1. Use of chemotherapy plus a monoclonal antibody against Her-2 for metastatic breast cancer that overexpresses Her-2
2. Weekly Trastuzumab and Paclitaxel therapy for metastatic breast cancer with analysis of efficacy by Her-2 immunophenotype and gene amplification
3. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
4. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of Paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
5. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
6. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
7. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in nodenegative breast carcinomas
8. C-erb B-2 amplification in node-negative human breast cancer
9. Clinical significance of Her-2/neu oncogene amplification in primary breast cancer
10. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer
11. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene coamplification units: Hst-1 1/int-2 and c-erb B-2/er-1
12. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
13. Significance of c-erbB-2 amplification and DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer
14. Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up
15. erbB2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
16. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
17. 20 Year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and tamoxifen efficacy
18. Prognostic importance of c-erbB-2 expression in breast cancer
19. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
20. Determination of Her-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization (FISH)
21. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
22. Increased Her-2 with US Food and Drug Administration approved antibody
23. Letter to editor
24. Breast cancer tests: Her-2/neu versus FISH
25. Fluorescence in situ hybridization (FISH) for detection of Her-2/neu amplification in breast cancer: A multicenter portability study
26. Comparative methodological analysis of erbB-2/Her-2 gene dosage, chromosomal copy number and protein over-expression in breast cancer tissues for diagnostic use
27. Sensitivity of Her-2/neu antibodies in archival tissue samples of invasive breast carcinomas
28. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization
29. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (Her-2/neu) gene status in breast carcinoma
30. The quality of Her-2/neu predictive immunohistochemistry: Something FISHy?
31. Her-2/neu gene amplification compared with Her-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
32. Her-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach
33. Comparison of Her-2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry
34. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: Comparison of results and correlation with survival
35. Comparison of PathVysion and INFORM fluorescence in situ hybridization kits for assessment of Her-2/neu status in breast carcinoma
36. Discrepancies in clinical laboratory testing of eligibility for Trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
37. Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): A fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression
38. In situ hybridization with RNA probes - An annotated recipe
39. Tissue in situ hybridization
40. Detection of human papillomavirus in cervical carcinoma: Comparison or peroxidase, Nanogold, and catalyzed reporter deposition (CARD)-Nanogold in situ hybridization
41. Clinical relevance of HPV 16/18 testing methods in cervical squamous cell carcinoma
42. A practical alternative for fluorescence in situ hybridization to detect Her-2/neu oncogene amplification in archival breast cancer samples